Related Experiment Video
Updated: Aug 11, 2026

Laparoscopic Non-Mesh Cerclage Pectopexy with Uterine Preservation for Pelvic Organ Prolapse
Published on: October 25, 2024
Levonorgestrel intrauterine system for endometrial protection
1Department of Women's Health, Solihull Hospital, Heart of England NHS Foundation Trust, Solihull, West Midlands, UK. david.sturdee@heartofengland.nhs.uk
Abstract:
Progestogen is added to estrogen in hormone replacement therapy solely to provide endometrial protection, so it is logical to deliver it to its site of action. The levonorgestrel intrauterine system, which delivers 20 mug levonorgestrel per day, is now licensed for use as the progestogen component of continuous combined hormone replacement therapy. No cases of endometrial hyperplasia or carcinoma, and no significant increase in endometrial thickness, have been reported in clinical trials. The bleeding profile is similar to that obtained with other types of continuous combined hormone replacement therapy. The levonorgestrel intrauterine system thus provides a potentially bleed-free alternative to sequential therapy for perimenopausal women.
Related Concept Videos
Intrauterine Drug Delivery Systems
Birth Control Methods
In Vitro Fertilization
The IVF process begins with ovarian stimulation, during which reproductive endocrinologists prescribe hormonal medications to stimulate the ovaries to produce multiple eggs instead of the single...
Ovarian Cycle
Uterus and Cervix
The uterus is securely anchored within the pelvic cavity by paired broad ligaments on either side. It is further stabilized by three pairs of...
Uterine Tubes